Dr. Sudipta Mohanty Scholarship for Underserved Communities in Medicine Announce Scholarship Winner
Dr. Sudipta Mohanty
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- The Dr. Sudipta Mohanty Scholarship for Underserved Communities in Medicine awarded its inaugural scholarship recipient on March 15, 2025. This one-time $1,000 award, founded by Dr. Sudipta Mohanty, is dedicated to supporting undergraduate and aspiring medical students who are passionate about improving healthcare access for underserved communities.
As a practicing physician and advocate for health equity, Dr. Sudipta Mohanty established this scholarship to empower students committed to addressing healthcare disparities. The overwhelming response from applicants nationwide highlights the growing enthusiasm among future healthcare professionals to make a meaningful impact in primary care and community health.
A Commitment to Future Medical Leaders
The Dr. Sudipta Mohanty Scholarship for Underserved Communities in Medicine was created to support students who share a commitment to primary care and serving marginalized populations. Applicants were required to submit an essay discussing the role of medicine in underserved communities and proposing innovative solutions to improve healthcare accessibility.
On March 15, 2025, one outstanding student will be selected as the recipient of this prestigious scholarship. The winning essay will be highlighted, recognizing the student's dedication to advancing healthcare equity and their potential to shape the future of medicine.
Dr. Sudipta Mohanty, the scholarship's founder, expressed his enthusiasm for the initiative:
"Throughout my career, I have seen firsthand the challenges faced by underserved communities in accessing quality healthcare. This scholarship is my way of encouraging the next generation of medical professionals to take an active role in bridging these gaps. The future of healthcare depends on individuals who are not only skilled but also deeply committed to equity and service."
Dr. Sudipta Mohanty's Vision and Impact
Dr. Sudipta Mohanty has dedicated his career to primary care, healthcare advocacy, and medical education. His journey began with an accelerated academic path, starting undergraduate studies at the age of 15 before earning his medical degree from the University of Pittsburgh. He later completed his residency at the University of California Riverside, solidifying his expertise in patient-centered care and health policy.
Through his work, Dr. Sudipta Mohanty has been a strong advocate for increasing access to healthcare services, particularly for marginalized communities. His scholarship reflects this ongoing commitment by encouraging and financially supporting students who aspire to make a difference in underserved areas.
Looking Ahead: March 15, 2025 Announcement
The selection process for the Dr. Sudipta Mohanty Scholarship for Underserved Communities in Medicine consisted of a dedicated panel reviewing applications to identify the student who best embodies the scholarship's mission. The winner was announced on March 15, 2025, with their story shared to inspire future applicants and medical professionals.
By recognizing students who align with Dr. Sudipta Mohanty's vision, this scholarship serves as both a financial resource and a platform to promote meaningful conversations about healthcare accessibility. Dr. Sudipta Mohanty looks forward to continuing this initiative and supporting future generations of healthcare leaders.
For more information about the Dr. Sudipta Mohanty Scholarship for Underserved Communities in Medicine, including future application opportunities, please visit https://drsudiptamohantyscholarship.com/.
Contact Info:
Spokesperson: Dr. Sudipta Mohanty
Organization: Dr. Sudipta Mohanty Scholarship
Website: https://drsudiptamohantyscholarship.com/
Email: apply@drsudiptamohantyscholarship.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/066ad169-2c62-406f-b0d8-2af00c9e5c8cSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Historic Win for Foster Youth and Families: A New Medicaid Benefit Becomes Reality
Los Angeles, CA, June 10, 2025 (GLOBE NEWSWIRE) -- Special Needs Network is proud to announce a major policy victory that will change lives across California. Thanks to our leadership and collaboration with state partners, a brand-new Medicaid benefit – the Fee-for-Service Behavioral Health Treatment (FFS BHT) benefit – will launch statewide on July 1, 2025. The new provider enrollment portal is open so providers can be ready to serve patients day one. SNN will be ready. 'This is a monumental step forward for California's foster youth and families,' said Areva Martin, President of Special Needs Network. 'Creating a brand-new Medicaid benefit in record time shows what's possible when community advocates, policymakers, and government agencies work together. We are proud that Special Needs Network's leadership helped drive this historic change — and we remain committed to ensuring that every child gets the care and support they deserve.' This breakthrough ensures that foster youth and all other children needing behavioral health therapy will finally have direct access to services under Medi-Cal, with more providers available and fewer barriers to care.,. Access will no longer be determined by whether a child has a managed care plan or FFS Medi-Cal or whether they are served by a regional center or not. Creating this new benefit involved: Securing federal approval for a new Medicaid State Plan. Building a statewide provider enrollment system. Establishing new billing codes and payment systems. Ensuring access for smaller community organizations and paraprofessionals. Eliminating referral barriers for families, physicians, and courts. SNN played a critical role at every step, providing technical expertise, real-world feedback, and advocacy that state officials have called 'invaluable.' Although the benefit launches July 1, work continues to refine the system and fully support providers, youth, and families. SNN will remain deeply involved in training, communications, system improvements, and monitoring to ensure a smooth rollout and lasting success. Priority processing is available through June 30. See the FAQs for providers here 'This win represents one of the fastest and most significant Medicaid benefit developments in California history — and it was fueled by SNN's dedication to children, families, and equitable access to care,' said Kristin Jacobson, a policy expert and long-time advocate who participated in this effort on behalf of SNN. To submit a PAVE application, agencies need to visit the PAVE (Provider Application and Validation for Enrollment) system portal: _________________________________________________________________________ (SNN) is a nonprofit grassroots organization responding to the crisis of autism and other developmental disabilities in underserved communities. We recognize the intersectionality of individuals with disabilities and that their fight for disability rights is inextricably tied to the fight for racial justice and the civil rights of all people. CONTACT: Special Needs Network communications@
Yahoo
24 minutes ago
- Yahoo
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss
Virtual platform now offers licensed physician care for testosterone therapy, GLP-1 weight loss support, and men's wellness programs across all 50 U.S. states San Diego, June 10, 2025 (GLOBE NEWSWIRE) -- a U.S.-based telehealth provider specializing in men's hormonal optimization and metabolic wellness, has officially expanded its clinical care services nationwide. This expansion supports a growing number of men seeking personalized healthcare solutions for low testosterone, weight challenges, and performance-related health issues—all from the convenience of their own home. Through its secure platform, connects patients to licensed U.S. physicians who evaluate medical history, review lab work, and prescribe clinically appropriate treatment programs. The company's services now reach patients in all 50 states, including those in remote or underserved areas where access to specialized care may be limited. 'Our mission is to make medically supervised hormone therapy and weight loss care more accessible for men everywhere,' said a spokesperson for 'This nationwide expansion reflects our commitment to safe, evidence-based telemedicine that empowers patients to take charge of their long-term health.' virtual platform is designed for ease of use, featuring: Fast, secure medical intake and scheduling Lab partnerships for at-home or local diagnostic testing Ongoing provider monitoring and patient support HIPAA-compliant communication channels Nationwide medication delivery where legally permitted All care is provided by board-certified physicians and licensed healthcare professionals who follow strict clinical guidelines. Treatment options may include testosterone replacement therapy (TRT), GLP-1-based metabolic weight programs, and supportive interventions for men's health, always following a personalized and physician-reviewed protocol. With recent updates to its website and mobile user interface, has also improved patient onboarding, reduced consultation wait times, and expanded clinical support availability. About is a telehealth company focused on optimizing men's health through medical evaluation, diagnostic testing, and customized treatment plans. The company specializes in testosterone therapy, weight management, and performance-focused wellness protocols—delivered entirely online through licensed U.S. providers. By combining technology with medical oversight, empowers men to pursue health goals with professional guidance and national reach. Contact: AM – 8:00 PM EDT Monday – Friday9:00 AM – 5:00 PM EDT Saturday – Sunday16776 Bernardo Center Dr. Suite 203, San Diego, CA 92128https:// SOURCE: Disclaimer This press release is for informational purposes only. provides healthcare services under licensed clinical supervision in compliance with state and federal regulations. No part of this release should be interpreted as medical advice or a substitute for an in-person doctor consultation. Treatment eligibility, outcomes, and availability may vary based on individual patient circumstances and state-specific regulations. CONTACT: 1-888-299-5088 support@ 8:00 AM – 8:00 PM EDT Monday – Friday 9:00 AM – 5:00 PM EDT Saturday – SundayError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
